3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, B-Cell
1
Interventions
fludarabine
2
Interleukin-2
2
Cyclophosphamide
2
toripalimab
1
lenvatinib
1
epigallocatechin gallate
1
avelumab
1
Zinc
1
Tissue Banks
1
Quercetin
1
Pemetrexed
1
Paclitaxel
1
Optical Fibers
1
Metformin
1
Ethiodized Oil
1
Docetaxel
1
Dihematoporphyrin Ether
1
Cisplatin
1
Carboplatin
1
Blood Specimen Collection
1
Biopsy, Needle
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
OTHER_GOV
×
avelumab
×
Clear all
NCT03244176
2024-07-30
AvR-CHOP
Austin Health
Phase EARLY_PHASE1
Active not recruiting
28 enrolled